CYTRX CORPORATION (NASDAQ:CYTR) Files An 8-K Other EventsItem 9.01Other Events
On September 21, 2017, CytRx Corporation (the "Company") issued a press release announcing that Glass Lewis & Co. has recommended that the Company's stockholders vote "FOR" the proposed reverse stock split at the upcoming special meeting of Company stockholders scheduled for October 17, 2017.
Attached hereto as Exhibit99.1, and incorporated herein by reference, is a copy of the press release.
Other Information
The Company and its directors, executive officers and advisors may be deemed to be participants in the solicitation of proxies in connection with the proposed reverse stock split to be considered at the special meeting of stockholders. Stockholders may obtain additional information regarding the interests of those participants by reading the Company's definitive proxy statement filed on August 29, 2017 and the Company's annual report on Form 10-K and quarterly reports on Form 10-Q, as filed with the SEC.
The definitive proxy statement and amendment was mailed to stockholders of record as of August 28, 2017, the record date established for voting on the proposed reverse stock split. Stockholders may obtain free copies of the definitive proxy statement and amendment and the Company's other SEC filings electronically by accessing the SEC's home page at http://www.sec.gov. Copies can also be obtained electronically on the Company's website at http://www.cytrx.com or, free of charge, upon written request to CytRx Corporation, Attn: Corporate Secretary, 11726 San Vicente Blvd., Suite 650, Los Angeles, CA 90049.
Item 9.01Financial Statement and Exhibits.
(d) Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Press Release issued on September 21, 2017 |
CYTRX CORP ExhibitEX-99.1 2 exh99_1.htm PRESS RELEASE DATED SEPTEMBER 21,…To view the full exhibit click here
About CYTRX CORPORATION (NASDAQ:CYTR)
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi’s sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.
